TriangleZanubrutinib (NCT06563596)
Zanubrutinib trial for Follicular Lymphoma (NCT06563596). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with relapsed or refractory CD20-positive follicular lymphoma, grades one to three-A, or marginal-zone lymphoma needing treatment. Prior anti-CD20 treatment is required; prior BTK inhibitors exclude participation.
The idea: combine epcoritamab injections, oral zanubrutinib and rituximab infusions for up to one year. Epcoritamab connects T cells to CD20-positive lymphoma cells; zanubrutinib blocks BTK growth signaling. Researchers assess complete responses at six months and safety. Bone-marrow biopsies and scans are required. Rituximab also targets CD20.
This phase 2 study plans 71 patients. Reid Merryman leads three recruiting US sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.